BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

20 related articles for article (PubMed ID: 8603335)

  • 1. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
    Choi CH; Ling V
    Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.
    Zhang S; Zhou L; Zhang M; Wang Y; Wang M; Du J; Gu W; Kui F; Li J; Geng S; Du G
    Front Pharmacol; 2019; 10():1658. PubMed ID: 32063859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aneugenic effects of epirubicin in somatic and germinal cells of male mice.
    Attia SM; Ahmad SF; Okash RM; Bakheet SA
    PLoS One; 2014; 9(10):e109942. PubMed ID: 25303090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.
    Odening KE; Li W; Rutz R; Laufs S; Fruehauf S; Fishelson Z; Kirschfink M
    Clin Exp Immunol; 2009 Feb; 155(2):239-48. PubMed ID: 19040611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.
    Pang E; Hu Y; Chan KY; Lai PB; Squire JA; Macgregor PF; Beheshti B; Albert M; Leung TW; Wong N
    Lab Invest; 2005 May; 85(5):664-74. PubMed ID: 15765123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
    Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
    Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
    Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
    Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.
    Knutsen T; Mickley LA; Ried T; Green ED; du Manoir S; Schröck E; Macville M; Ning Y; Robey R; Polymeropoulos M; Torres R; Fojo T
    Genes Chromosomes Cancer; 1998 Sep; 23(1):44-54. PubMed ID: 9713996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
    Belhoussine R; Morjani H; Manfait M
    Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies.
    Ganapathi R; Hoeltge G; Casey G; Grabowski D; Neelon R; Ford J
    Cancer Genet Cytogenet; 1996 Feb; 86(2):116-9. PubMed ID: 8603335
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.